Business
Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer
CTA submission positions Silexion for European Phase 2/3 trial of SIL204 in KRAS-driven pancreatic cancer, with Germany serving as Reference Member State for the EU programGrand Cayman, Cayman Islands, April 28, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the recent successful submission of a Clinical Trial Application
About this update from Silexion Therapeutics Corp
[{"type":"image","alt":"Silexion Therapeutics Corp","displaySize":"","headline":null,"caption":"Silexion Therapeutics Corp","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":116,"url":"https://media.zenfs.com/en/globenewswire.com/0e108fa5d2c179a927ea7dc4257aea29"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/UgjLQZLNUAs3Ao0leE7DGQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2Mg--/https://media.zenfs.com/en/globenewswire.com/0e108fa5d2c179a927ea7dc4257aea29","width":300,"height":116}},"lazy":false},{"type":"text","content":"CTA submission positions Silexion for European Phase 2/3 trial of SIL204 in KRAS-driven pancreatic cancer, with Germany serving as Reference Member State for the EU program","length":172,"tagName":"p"},{"type":"text","content":"Grand Cayman, Cayman Islands, April 28, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the recent successful submission of a Clinical Trial Application (CTA) to Germany for its planned Phase 2/3 clinical trial of its lead, small interfering RNA (siRNA) product candidate, SIL204, in patients with locally advanced pancreatic cancer (LAPC). The CTA was submitted through the EU Clinical Trials Information System (CTIS), with Germany serving as the Reporting Member State - the country that will lead the scientific assessment of the trial across the European Union.","length":762,"tagName":"p"},{"type":"text","content":"The submission represents a pivotal regulatory milestone in Silexion's clinical development program and marks the Company's entry into the European regulatory process for its next-generation siRNA therapy targeting mutated KRAS. The filing was informed by the positive Scientific Advice received from Germany's Federal Institute for Drugs and Medical Devices (BfArM, Bundesinstitut für Arzneimittel und Medizinprodukte) announced in December 2025, and follows the recent approval from the Israeli Ministry of Health to initiate the same Phase 2/3 trial in Israel.","length":575,"tagName":"p"},{"type":"text","content":"The application is supported by a comprehensive regulatory package, including completed two-species toxicology studies confirming no systemic organ toxicity,...